The FDA issued what's euphemistically known as an "approvable" letter, saying that Provenge could be approved in the future if Dendreon passes more hurdles.
Dr Gabrielle Heathcote, vice chair of the CHC, expressed concerned that Ms Griffiths' response letter had not referred the council's concerns over what they considered to be "inadequacy and failures of the LHB's consultation process".